Literature DB >> 21224011

National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.

Michael R Bishop1, Edwin P Alyea, Mitchell S Cairo, J H Frederik Falkenburg, Carl H June, Nicolaus Kröger, Richard F Little, Jeffrey S Miller, Steven Z Pavletic, David L Porter, Stanley R Riddell, Koen van Besien, Alan S Wayne, Daniel J Weisdorf, Roy S Wu, Sergio Giralt.   

Abstract

The National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation was organized and convened to identify, prioritize, and coordinate future research activities related to relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Each of the Workshop's 6 Working Committees has published individual reports of ongoing basic, translational, and clinical research and recommended areas for future research related to the areas of relapse biology, epidemiology, prevention, and treatment. This document summarizes each committee's recommendations and suggests 3 major initiatives for a coordinated research effort to address the problem of relapse after allo-HSCT: (1) to establish multicenter correlative and clinical trial networks for basic/translational, epidemiologic, and clinical research; (2) to establish a network of biorepositories for the collection of samples before and after allo-HSCT to aid in laboratory and clinical studies; and (3) to further refine, implement, and study the Workshop-proposed definitions for disease-specific response and relapse and recommendations for monitoring of minimal residual disease. These recommendations, in coordination with ongoing research initiatives and transplantation organizations, provide a research framework to rapidly and efficiently address the significant problem of relapse after allo-HSCT. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21224011      PMCID: PMC3102296          DOI: 10.1016/j.bbmt.2010.12.713

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  33 in total

1.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.

Authors:  R Storb; C Yu; J L Wagner; H J Deeg; R A Nash; H P Kiem; W Leisenring; H Shulman
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

2.  Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.

Authors:  Roberto Bellucci; Edwin P Alyea; Edie Weller; Antoinette Chillemi; Ephraim Hochberg; Catherine J Wu; Christine Canning; Robert Schlossman; Robert J Soiffer; Kenneth C Anderson; Jerome Ritz
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

3.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

4.  The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?

Authors:  S Slavin; A Ackerstein; E Naparstek; R Or; L Weiss
Journal:  Bone Marrow Transplant       Date:  1990-09       Impact factor: 5.483

5.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

6.  The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation.

Authors:  P Raanani; F Dazzi; J Sohal; R M Szydlo; F van Rhee; A Reiter; F Lin; J M Goldman; N C Cross
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

Review 7.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

8.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

9.  Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.

Authors:  D L Porter; M S Roth; C McGarigle; J L Ferrara; J H Antin
Journal:  N Engl J Med       Date:  1994-01-13       Impact factor: 91.245

10.  Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants.

Authors:  B Shank; F C Chu; R Dinsmore; N Kapoor; D Kirkpatrick; H Teitelbaum; A Reid; P Bonfiglio; L Simpson; R J O'Reilly
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-11       Impact factor: 7.038

View more
  18 in total

1.  Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.

Authors:  Nirali N Shah; Ulrike Bacher; Terry Fry; Katherine R Calvo; Maryalice Stetler-Stevenson; Diane C Arthur; Roger Kurlander; Kristin Baird; Barbara Wise; Sergio Giralt; Michael Bishop; Nancy M Hardy; Alan S Wayne
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

Review 2.  The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years.

Authors:  Sarah A Wall; Steven Devine; Sumithira Vasu
Journal:  Blood Rev       Date:  2017-07-15       Impact factor: 8.250

Review 3.  The role of second transplants for leukemia.

Authors:  Daniel Weisdorf
Journal:  Best Pract Res Clin Haematol       Date:  2016-10-19       Impact factor: 3.020

4.  Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells.

Authors:  Carsten Berges; Manik Chatterjee; Max S Topp; Hermann Einsele
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

5.  Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia.

Authors:  Navneet S Majhail; Ruta Brazauskas; Anna Hassebroek; Christopher N Bredeson; Theresa Hahn; Gregory A Hale; Mary M Horowitz; Hillard M Lazarus; Richard T Maziarz; William A Wood; Susan K Parsons; Steven Joffe; J Douglas Rizzo; Stephanie J Lee; Brandon M Hayes-Lattin
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-29       Impact factor: 5.742

6.  Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.

Authors:  Gita Thanarajasingam; Haesook T Kim; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Philippe Armand
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-27       Impact factor: 5.742

7.  Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.

Authors:  Brian C Shaffer; Marko Modric; Maryalice Stetler-Stevenson; Diane C Arthur; Seth M Steinberg; David J Liewehr; Daniel H Fowler; Robert P Gale; Michael R Bishop; Steven Z Pavletic
Journal:  Exp Hematol       Date:  2013-05-18       Impact factor: 3.084

8.  Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.

Authors:  Iskra Pusic; Jaebok Choi; Mark A Fiala; Feng Gao; Matthew Holt; Amanda F Cashen; Ravi Vij; Camille N Abboud; Keith E Stockerl-Goldstein; Meghan A Jacoby; Geoffrey L Uy; Peter Westervelt; John F DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2015-06-05       Impact factor: 5.742

9.  Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.

Authors:  Xiaowen Tang; Gheath Alatrash; Jing Ning; Haroon Jakher; Patricia Stafford; Madhushree Zope; Elizabeth J Shpall; Roy B Jones; Richard E Champlin; Peter F Thall; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-13       Impact factor: 5.742

10.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.

Authors:  Alan S Wayne; Sergio Giralt; Nicolaus Kröger; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.